Head to Head Review: Rockwell Medical (NASDAQ:RMTI) versus PURE Bioscience (OTCMKTS:PURE)

Rockwell Medical (NASDAQ:RMTI) and PURE Bioscience (OTCMKTS:PURE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation and Earnings

This table compares Rockwell Medical and PURE Bioscience”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rockwell Medical	$69.26 million	0.39	-$5.31 million	($0.15)	-4.50
PURE Bioscience	$2.20 million	3.55	-$2.40 million	($0.03)	-2.00

PURE Bioscience has lower revenue, but higher earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than PURE Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Rockwell Medical and PURE Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rockwell Medical	1	0	1	0	2.00
PURE Bioscience	0	0	0	0	0.00

Rockwell Medical presently has a consensus target price of $2.00, suggesting a potential upside of 195.99%. Given Rockwell Medical’s stronger consensus rating and higher probable upside, research analysts clearly believe Rockwell Medical is more favorable than PURE Bioscience.

Risk and Volatility

Rockwell Medical has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, PURE Bioscience has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500.

Institutional & Insider Ownership

23.3% of Rockwell Medical shares are owned by institutional investors. 3.6% of Rockwell Medical shares are owned by company insiders. Comparatively, 35.6% of PURE Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Rockwell Medical and PURE Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rockwell Medical	-7.98%	-15.41%	-9.62%
PURE Bioscience	-108.77%	N/A	-356.86%

Summary

Rockwell Medical beats PURE Bioscience on 8 of the 14 factors compared between the two stocks.

About Rockwell Medical

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

About PURE Bioscience

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.